Metabolic Syndrome Strongly Linked to Difficult-to-Treat Psoriatic Arthritis Phenotype
A new cross-sectional study has identified a strong association between metabolic syndrome (MetS) and the development of a difficult-to-treat (D2T) phenotype in patients with psoriatic arthritis (PsA), highlighting the need to address metabolic comorbidities as part of a comprehensive disease management strategy.
The study included 182 patients with PsA meeting Classification Criteria for Psoriatic Arthritis (CASPAR), evaluated at the Rheumatology Clinic of Fondazione Policlinico Campus Bio-Medico of Rome. Disease activity and the presence of MetS were assessed, with MetS defined by the National Cholesterol Education Program Adult Treatment Panel III criteria. The D2T phenotype was identified based on revised Rheumatoid Arthritis European Alliance of Associations for Rheumatology (EULAR) criteria adapted for PsA.
Overall, 42.94% of patients with PsA met the criteria for MetS. Among patients with a D2T phenotype (n=66), 81.82% had MetS, compared to only 29.37% of those without D2T status. This difference was statistically significant (p<0.0001), suggesting a strong link between metabolic dysfunction and poor disease control.
Logistic regression confirmed that MetS is a robust independent predictor of D2T PsA, with an odds ratio (OR) of 7.56 (95% CI 2.53 to 22.56, p<0.0001). Path analysis further validated this relationship, showing that MetS contributes directly to the development of treatment-resistant disease.
The authors stated, “MetS is strongly associated with a D2T phenotype in PsA,” and added that this comorbidity may play a critical role in driving disease severity and limiting therapeutic response.
PsA is known for its clinical heterogeneity, presenting with varying combinations of peripheral arthritis, axial disease, enthesitis, and dactylitis. Patients with D2T PsA often require multiple lines of therapy and continue to experience high disease activity or functional limitations despite optimal treatment. Understanding modifiable contributors to the D2T state is essential for improving outcomes.
This study suggests that MetS—characterized by obesity, insulin resistance, dyslipidemia, and hypertension—may promote inflammatory pathways that increase disease burden and interfere with therapeutic efficacy. The findings underscore the importance of identifying and addressing MetS early in the disease course.
For practicing rheumatologists, the key clinical implication is that routine screening for metabolic comorbidities in PsA should be integrated into treatment planning. Patients with MetS may be at heightened risk for refractory disease, and failure to manage metabolic dysfunction may undermine otherwise appropriate immunomodulatory therapy.
The authors conclude, “Addressing metabolic dysfunction may be crucial in optimising therapeutic outcomes in PsA management.”
These findings support a multidisciplinary approach to PsA care, where metabolic health is prioritized alongside disease activity monitoring and pharmacologic treatment. Incorporating weight management, cardiovascular risk reduction, and glycemic control may be essential components of care in patients with or at risk of developing D2T PsA.
Reference
Currado D, Trunfio F, Saracino F, et al. Patients with psoriatic arthritis and comorbid metabolic syndrome show a difficult-to-treat phenotype: another mosaic tile in the definition of a still undefined subset of patients. RMD Open. 2025;11(2):e005717. Published online June 22, 2025. doi:10.1136/rmdopen-2025-005717
